Tanacetum parthenium and Salix alba (Mig-RL®) combination in migraine prophylaxis: A prospective, open-label study

Clinical Drug Investigation

Volumn 26, Issue 5, 2006, Pages 287-296

  Shrivastava, R ^a   Pechadre, J C ^b   John, G W ^a  

^a ZAC de Lavaur   (France)

^b HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; CAFERGOT; DIHYDROERGOTAMINE; IBUPROFEN; KETOPROFEN; METOCLOPRAMIDE; MIG RL; PARACETAMOL; PLANT EXTRACT; SALIX EXTRACT PLUS TANACETUM PARTHENIUM EXTRACT; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CAPSULE; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MEMORY; MIGRAINE WITHOUT AURA; PAIN ASSESSMENT; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; SELF EVALUATION; TANACETUM PARTHENIUM; WILLOW;

ADULT; CAPSULES; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUGS, NON-PRESCRIPTION; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; NONPRESCRIPTION DRUGS; PLANT EXTRACTS; PROSPECTIVE STUDIES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SALIX; TANACETUM PARTHENIUM; TIME FACTORS; TREATMENT OUTCOME;

EID: 33744932931     PISSN: 11732563     EISSN: 11732563     Source Type: Journal    
DOI: 10.2165/00044011-200626050-00006     Document Type: Article

References (41)

1. Silberstein SD, Lipton RB, Dalessio DJ. Overview, diagnosis and classification of headache. In: Silberstein SD, Lipton RB, Dalessio DJ, editors. Wolff's headache and other head pain. 7th ed. New York: Oxford University Press, 2001: 6-26
2. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N Engl J Med 2002; 346 (4): 257-70
3. Lipton RB, Diamond S, Reed M, et al. Migraine diagnosis and treatment: results from the American Migraine Study: II. Headache 2001; 41 (7): 638-45
4. Ferrari MD, Goadsby PJ, Roon KI, et al. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002; 22 (8): 633-58
5. Massiou H, Bousser MG. Prophylactic drug treatment of migraine. Rev Neurol (Paris) 2005; 161 (6-7): 681-4
6. Diener HC, Limmroth V. Advances in pharmacological treatment of migraine. Expert Opin Investig Drugs 2001; 10 (10): 1831-45
7. Pietrobon D, Striessnig J. Neurobiology of migraine. Nat Rev Neurosci 2003; 4 (5): 386-98
8. Waeber C, Moskowitz MA. Therapeutic implications of central and peripheral neurologic mechanisms in migraine. Neurology 2003; 61 (8 Suppl. 4): S9-S20
9. Goadsby PJ. Can we develop neurally acting drugs for the treatment of migraine? Nat Rev Drug Discov 2005; 4 (9): 741-50
10. Welch KM. Contemporary concepts of migraine pathogenesis. Neurology 2003; 61 (8 Suppl. 4): S2-8
11. Welch KM. Brain hyperexcitability: the basis for antiepileptic drugs in migraine prevention. Headache 2005; 45 Suppl. 1: S25-32
12. Humphrey PP, Feniuk W, Perren MJ, et al. Serotonin and migraine. Ann N Y Acad Sci 1990; 600: 587-600
13. Humphrey PP. 5-Hydroxytryptamine and the pathophysiology of migraine. J Neurol 1991; 238 Suppl. 1: S38-44
14. Lance JW. 5-Hydroxytryptamine and its role in migraine. Eur Neurol 1991; 31 (5): 279-81
15. Sicuteri F, Testi A, Anselmi B. Biochemical investigations in headache: increase in the hydroxyindoleacetic acid excretion during migraine attacks. Int Arch Allerg 1961; 19: 55-8
16. Hamel E, Saxena PR. 5-Hydroxytryptamine involvement in migraines. In: Olesen J, Tfelt-Hansen P, Welch KMA, et al., editors. The headaches. Chap. 29. 3rd ed. Pennsylvania: Lippincott Williams & Wilkins, 2006: 275-280
17. Feniuk W, Humphrey PP, Perren MJ, et al. Rationale for the use of 5-HT1-like agonists in the treatment of migraine. J Neurol 1991; 238 Suppl. 1: S57-61
18. John GW, Goadsby PJ. Triptan signal transduction. In: Olesen J, Tfelt-Hansen P, Welch KMA, et al., editors. The headaches. Chap. 21. 3rd ed. Pennsylvania: Lippincott Williams & Wilkins, 2006: 203-211
19. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000; 60 (6): 1259-87
20. Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia 2002; 22 (7): 491-512
21. Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev 2004; (1): CD002286; 1-10
22. Barsby RW, Salan U, Knight DW, et al. Feverfew and vascular smooth muscle: extracts from fresh and dried plants show opposing pharmacological profiles, dependent upon sesquiterpene lactone content. Planta Med 1993; 59 (1): 20-5
23. Bejar E. Parthenolide inhibits the contractile responses of rat stomach fundus to fenfluramine and dextroamphetamine but not serotonin. J Ethnopharmacol 1996; 50 (1): 1-12
24. Mittra S, Datta A, Singh SK, et al. 5-Hydroxytryptamine-inhibiting property of feverfew: role of parthenolide content. Acta Pharmacol Sin 2000; 21 (12): 1106-14
25. Weber JT, O'Connor MF, Hayataka K, et al. Activity of parthenolide at 5HT2A receptors. J Nat Prod 1997; 60 (6): 651-3
26. Shrivastava R, John GW. Ligand binding study of the interaction of Tanacetum parthenium and Salix alba with 5-HT receptors associated with headache. 2006 (Submitted for publication)
27. Headache Classification Committee of the International Headache Society. ICHD-II. Cephalalgia 2004; 24 Suppl. 1: 1-160
28. Murphy JJ, Heptinstall S, Mitchell JR. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 1988; II (8604): 189-92
29. Diener HC, Pfaffenrath V, Schnitker J, et al. Efficacy and safety of 6.25mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention: a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia 2005; 25 (11): 1031-41
30. Johnson ES, Kadam NP, Hylands DM, et al. Efficacy of feverfew as prophylactic treatment of migraine. BMJ 1985; 291 (6495): 569-73
31. De Weerdt CJ, Bootsma HPR, Hendricks H. Herbal medicines in migraine prevention: randomized double-blind placebo-controlled crossover trial of a feverfew preparation. Phytomedicine 1996; 3: 225-30
32. Pfaffenrath V, Diener HC, Fischer M, et al. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis: a double-blind, multicentre, randomized placebo controlled dose-response study. Cephalalgia 2002; 22 (7): 523-32
33. Diener HC. Placebo and headache [abstract]. Cephalalgia 2005; 25: 841
34. Palevitch D, Earon G, Carasso R. Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: a double-blind placebo-controlled study. Phytother Res 1997; 11: 508-11
35. Khayyal MT, El-Ghazaly MA, Abdallah DM, et al. Mechanisms involved in the anti-inflammatory effect of a standardized willow bark extract. Arzneimittel Forschung 2005; 55 (11): 677-87
36. Groenewegen WA, Heptinstall S. A comparison of the effects of an extract of feverfew and parthenolide, a component of feverfew, on human platelet activity in-vitro. J Pharm Pharmacol 1990; 42 (8): 553-7
37. Reuter U, Chiarugi A, Bolay H, et al. Nuclear factor-kappaB as a molecular target for migraine therapy. Ann Neurol 2002; 51 (4): 507-16
38. Kwok BH, Koh B, Ndubuisi MI, et al. The anti-inflammatory prevennatural product parthenolide from the medicinal herb feverfew directly binds to and inhibits IkappaB kinase. Chem Biol 2001; 8 (8): 759-66
39. Tassorelli C, Greco R, Morazzoni P, et al. Parthenolide is the component of Tanacetum parthenium that inhibits nitroglycerin-induced Fos activation: studies in an animal model of migraine. Cephalalgia 2005; 25 (8): 612-21
40. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 2004; 55 (1): 19-26
41. Tfelt-Hansen P, Block G, Dahlof C, et al. Guidelines for controlled trials of drugs in migraine, 2nd ed. Cephalalgia 2000; 20 (9): 765-86